Lysyl oxidases: Emerging biomarkers and therapeutic targets for various diseases

• Main Authors: Nan Yang, Dan-Feng Cao, Xi-Xi Yin, Hong-Hao Zhou, Xiao-Yuan Mao
• Format: Article
• Language: English
• Published: Elsevier 2020-11-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Lysyl oxidases; Extracellular matrix remodeling; Hypoxia; Epithelial-to-mesenchymal transition; Disease pathology; Therapeutic target
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332220309847

Therapeutic targeting of extracellular proteins has attracted huge attention in treating human diseases. The lysyl oxidases (LOXs) are a family of secreted copper-dependent enzymes which initiate the covalent crosslinking of collagen and elastin fibers in the extracellular microenvironment, thereby facilitating extracellular matrix (ECM) remodeling and ECM homeostasis. Apart from ECM-dependent roles, LOXs are also involved in other biological processes such as epithelial-to-mesenchymal transition (EMT) and transcriptional regulation, especially following hypoxic stress. Dysregulation of LOXs is found to underlie the onset and progression of multiple pathologies, such as carcinogenesis and cancer metastasis, fibrotic diseases, neurodegeneration and cardiovascular diseases. In this review, we make a comprehensive summarization of clinical and experimental evidences that support roles of for LOXs in disease pathology and points out LOXs as promising therapeutic targets for improving prognosis. Additionally, we also propose that LOXs reshape cell-ECM interaction or cell-cell interaction due to ECM-dependent and ECM-independent roles for LOXs. Therapeutic intervention of LOXs may have advantages in the maintenance of communication between ECM and cell or intercellular signaling, finally recovering organ function.